Diabetes Technology: Uptake, Outcomes, Barriers, and the Intersection With Distress

Overview

Journal J Diabetes Sci Technol

Specialty Endocrinology

Date 2016 May 29

PMID 27234809

Citations 50

Authors

Diana Naranjo

Molly L Tanenbaum

Esti Iturralde

Korey K Hood

Affiliations

Soon will be listed here.

Abstract

Patients managing type 1 diabetes have access to new technologies to assist in management. This manuscript has two aims: 1) to briefly review the literature on diabetes technology use and how this relates to psychological factors and 2) to present an example of human factors research using our data to examine psychological factors associated with technology use. Device/technology uptake and use has increased over the years and at present day is a common clinical practice. There are mixed results in terms of health and psychosocial outcomes, with specific subgroups doing better than others with technology. Our data demonstrated that patients have moderately elevated diabetes distress across differing types of technology used, from low-tech to high-tech options, possibly meaning that technology does not add or take away distress. In addition, users on multiple daily injections compared to all other technology groups have less positive attitudes about technology. Finally, we discuss implications for clinical practice and future research.

Citing Articles

International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024 Diabetes Technologies: Glucose Monitoring.

Tauschman M, Cardona-Hernandez R, DeSalvo D, Hood K, Laptev D, Lindholm Olinder A Horm Res Paediatr. 2025; 97(6):615-635.

PMID: 39884260 PMC: 11854985. DOI: 10.1159/000543156.

Psychosocial outcomes in a diverse sample of youth and their families who initiated continuous glucose monitoring within the first year of type 1 diabetes diagnosis.

Addala A, Ritter V, Schneider-Utaka A, Alamarie S, Pang E, Balistreri I Diabetes Obes Metab. 2024; 27(2):933-943.

PMID: 39604317 PMC: 11700754. DOI: 10.1111/dom.16093.

Diabetes Device Satisfaction Among Adolescents Living With Type 1 Diabetes and Their Parents.

Wong J, Alamarie S, Hanes S, Flores H, Ngo J, Schneider-Utaka A J Diabetes Sci Technol. 2024; :19322968241296135.

PMID: 39529259 PMC: 11571572. DOI: 10.1177/19322968241296135.

Hypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST): protocol for a 24-week hybrid type 1 randomised controlled trial of a fully online psycho-educational programme for adults with type 1 diabetes.

Halliday J, Holmes-Truscott E, Thuraisingam S, Soholm U, Chatterton M, Russell-Green S Trials. 2024; 25(1):725.

PMID: 39468682 PMC: 11520494. DOI: 10.1186/s13063-024-08556-1.

Time for a Reframe: Shifting Focus From Continuous Glucose Monitor Uptake to Sustainable Use to Optimize Outcomes.

Mayberry L, Nelson L, Bergner E, Raymond J, Tanenbaum M, Jaser S J Diabetes Sci Technol. 2024; :19322968241268560.

PMID: 39143688 PMC: 11572238. DOI: 10.1177/19322968241268560.

References

. Validation of measures of satisfaction with and impact of continuous and conventional glucose monitoring. Diabetes Technol Ther. 2010; 12(9):679-84. PMC: 3045572. DOI: 10.1089/dia.2010.0015. View

Updike S, Hicks G . The enzyme electrode. Nature. 1967; 214(5092):986-8. DOI: 10.1038/214986a0. View

Wood J, Moreland E, Volkening L, Svoren B, Butler D, Laffel L . Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care. 2006; 29(11):2355-60. DOI: 10.2337/dc06-1141. View

Miller K, Foster N, Beck R, Bergenstal R, DuBose S, DiMeglio L . Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015; 38(6):971-8. DOI: 10.2337/dc15-0078. View

Beck R, Lawrence J, Laffel L, Wysocki T, Xing D, Huang E . Quality-of-life measures in children and adults with type 1 diabetes: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring randomized trial. Diabetes Care. 2010; 33(10):2175-7. PMC: 2945155. DOI: 10.2337/dc10-0331. View

OConnell M, Donath S, ONeal D, Colman P, Ambler G, Jones T . Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia. 2009; 52(7):1250-7. DOI: 10.1007/s00125-009-1365-0. View

Pickup J, Keen H, Parsons J, Alberti K . Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J. 1978; 1(6107):204-7. PMC: 1602534. DOI: 10.1136/bmj.1.6107.204. View

Polonsky W, Hessler D . What are the quality of life-related benefits and losses associated with real-time continuous glucose monitoring? A survey of current users. Diabetes Technol Ther. 2013; 15(4):295-301. DOI: 10.1089/dia.2012.0298. View

Norgaard K, Shin J, Welsh J, Gjessing H . Performance and acceptability of a combined device for insulin infusion and glucose sensing in the home setting. J Diabetes Sci Technol. 2015; 9(2):215-20. PMC: 4604571. DOI: 10.1177/1932296814567326. View

10.

Liberman A, Buckingham B, Phillip M . Diabetes technology and the human factor. Diabetes Technol Ther. 2014; 16 Suppl 1:S110-8. PMC: 3920750. DOI: 10.1089/dia.2014.1513. View

11.

Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, Hoogma R . The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012; 55(12):3155-62. PMC: 3483098. DOI: 10.1007/s00125-012-2708-9. View

12.

Luo P, Cheng Q, Chen B, Li Y, Wu J, Zhang X . Hypoglycemia and blood glucose fluctuations in the application of a sensor-augmented insulin pump. Diabetes Technol Ther. 2013; 15(12):984-9. DOI: 10.1089/dia.2013.0078. View

13.

Misso M, Egberts K, Page M, OConnor D, Shaw J . Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010; (1):CD005103. DOI: 10.1002/14651858.CD005103.pub2. View

14.

Wong J, Foster N, Maahs D, Raghinaru D, Bergenstal R, Ahmann A . Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care. 2014; 37(10):2702-9. PMC: 4392936. DOI: 10.2337/dc14-0303. View

15.

Grunberger G, Abelseth J, Bailey T, Bode B, Handelsman Y, Hellman R . Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014; 20(5):463-89. DOI: 10.4158/EP14145.PS. View

16.

Pihoker C, Badaru A, Anderson A, Morgan T, Dolan L, Dabelea D . Insulin regimens and clinical outcomes in a type 1 diabetes cohort: the SEARCH for Diabetes in Youth study. Diabetes Care. 2012; 36(1):27-33. PMC: 3526205. DOI: 10.2337/dc12-0720. View

17.

Gimenez M, Lara M, Conget I . Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study. Diabetes Technol Ther. 2010; 12(7):517-21. DOI: 10.1089/dia.2010.0028. View

18.

de Bock M, Gunn A, Holt J, Derraik J, Reed P, Cutfield W . Impact of insulin pumps on glycaemic control in a pump-naïve paediatric regional population. J Paediatr Child Health. 2011; 48(3):247-52. DOI: 10.1111/j.1440-1754.2011.02245.x. View

19.

Wong J, Dolan L, Yang T, Hood K . Insulin pump use and glycemic control in adolescents with type 1 diabetes: Predictors of change in method of insulin delivery across two years. Pediatr Diabetes. 2014; 16(8):592-9. PMC: 4458222. DOI: 10.1111/pedi.12221. View

20.

Markowitz J, Pratt K, Aggarwal J, Volkening L, Laffel L . Psychosocial correlates of continuous glucose monitoring use in youth and adults with type 1 diabetes and parents of youth. Diabetes Technol Ther. 2012; 14(6):523-6. PMC: 3359621. DOI: 10.1089/dia.2011.0201. View